Potency assay (cells):
In HEK293 cells, repaglinide inhibited Kir6.2/SUR-1 currents in patch-clamp assay. In islets isolated from Wistar rats, Repaglinide induced insulin release (2.1 ng/islet/hour) at 5 mM glucose.
Target engagement assay (cells):
Yes, patch clamp and competitive binding assays using wild-type (binds repaglinide) and mutant (S1237Y, defective in binding repaglinide) SUR1.